23andMe recently started offering customers new Genetic Health Risk reports that have received FDA authorization. Below we’ve highlighted some important features in these reports to help you get more out...

April is Parkinson’s Awareness Month and this year it also marks the eighth anniversary of 23andMe’s Parkinson’s Research Community, which introduced a game-changing model for science, one that leverages online...

The U.S. Food and Drug Administration granted 23andMe authorization to offer ten genetic health risk reports including late-onset Alzheimer’s disease, Parkinson’s disease, celiac disease, and a condition associated with harmful...

Attending the annual American Society of Human Genetics meeting in Vancouver next week?We’d love to hear from you! Attend our talks, come by our posters, and find us at our...

After four days in Berlin attending the massive annual meeting of the International Parkinson’s and Movement Disorders Society, 23andMe Parkinson’s Community manager, Paul Cannon, PhD, came back hopeful for the...

In his last fight– the one against Parkinson’s – Muhammad Ali went the distance finally succumbing in early June to complications from a respiratory problem.He was 74. In the more...

To mark Parkinson’s Awareness Month, we’re taking a moment to look at some of the accomplishments 23andMe has made in the study of the disease in a relatively short time....

The panel discussing Parkinson’s Progression Marker Initiative at the MJFF’s Parkinson’s Disease Therapeutics Conference in New York. From implanting cells into the brain to prevent the loss of dopamine producing...

As federal regulators listened, patients told them of their symptoms – the sleepless nights, the days with uncontrollable tremors or the little struggles simply maintaining their balance. Paul Cannon, 23andMe’s...

A team of researchers has developed a simple and non-invasive approach that uses genetic data in combination with other demographic and biomarker information to accurately distinguish those with and without...